Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueGoodwillGoodwill & IntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Akebia Therapeutics (AKBA) Non-Current Deffered Revenue (2016 - 2024)

Akebia Therapeutics (AKBA) has disclosed Non-Current Deffered Revenue for 8 consecutive years, with $43.3 million as the latest value for Q1 2024.

  • On a quarterly basis, Non-Current Deffered Revenue changed 0.0% to $43.3 million in Q1 2024 year-over-year; TTM through Mar 2024 was $43.3 million, a 0.0% change, with the full-year FY2023 number at $43.3 million, changed 0.0% from a year prior.
  • Non-Current Deffered Revenue was $43.3 million for Q1 2024 at Akebia Therapeutics, roughly flat from $43.3 million in the prior quarter.
  • In the past five years, Non-Current Deffered Revenue ranged from a high of $65.4 million in Q1 2022 to a low of $16.6 million in Q2 2021.
  • A 5-year average of $37.3 million and a median of $43.3 million in 2022 define the central range for Non-Current Deffered Revenue.
  • Peak YoY movement for Non-Current Deffered Revenue: plummeted 54.91% in 2021, then skyrocketed 238.65% in 2022.
  • Akebia Therapeutics' Non-Current Deffered Revenue stood at $25.3 million in 2020, then dropped by 15.27% to $21.5 million in 2021, then skyrocketed by 101.62% to $43.3 million in 2022, then changed by 0.0% to $43.3 million in 2023, then changed by 0.0% to $43.3 million in 2024.
  • Per Business Quant, the three most recent readings for AKBA's Non-Current Deffered Revenue are $43.3 million (Q1 2024), $43.3 million (Q4 2023), and $43.3 million (Q3 2023).